Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B

<p><strong>Background/aims</strong></p> <p>Five nucleoside/nucleotide treatments are now available for chronic hepatitis B (CHB). This meta-analysis aimed to assess the relative efficacy of adefovir, entecavir, lamivudine, telbivudine, tenofovir disoproxil fumarate (TDF...

Full description

Bibliographic Details
Main Authors: Dakin, H, Fidler, C, Harper, C
Format: Journal article
Language:English
Published: Elsevier 2011
_version_ 1826311511733174272
author Dakin, H
Fidler, C
Harper, C
author_facet Dakin, H
Fidler, C
Harper, C
author_sort Dakin, H
collection OXFORD
description <p><strong>Background/aims</strong></p> <p>Five nucleoside/nucleotide treatments are now available for chronic hepatitis B (CHB). This meta-analysis aimed to assess the relative efficacy of adefovir, entecavir, lamivudine, telbivudine, tenofovir disoproxil fumarate (TDF), and nucleos(t)ide combinations in the treatment of CHB.</p> <p><strong>Methods</strong></p> <p>A systematic review of MEDLINE and the Cochrane library was conducted to identify all studies evaluating these nucleos(t)ides in adults with CHB. Randomized controlled trials were included in the meta-analysis if they reported the proportion of patients with undetectable hepatitis B virus (HBV) DNA or hepatitis B e antigen (HBeAg) loss/seroconversion at 1 year. Bayesian mixed treatment comparison meta-analyses were conducted in WinBUGS to assess relative efficacy.</p> <p><strong>Results</strong></p> <p>A random-effects meta-analysis of trials on treatment-naive patients with HBeAg-positive CHB demonstrated that 94% of patients will achieve HBV DNA < 300 copies/ml after 1 year with TDF, compared with 73% for entecavir, 50% for adefovir, and 38% for lamivudine. There was a 97.7% probability that TDF enabled a greater proportion of patients to achieve HBV DNA < 300 copies/ml at 1 year than all other treatments considered in the analysis. TDF was significantly superior to all nucleos(t)ides for this outcome at the 0.05 level. There were no statistically significant differences between nucleos(t)ides in HBeAg seroconversion at 1 year, based on a fixed-effects meta-analysis in the same population. More trials on HBeAg-negative and drug-resistant patients are required to facilitate meta-analyses for these subgroups.</p> <p><strong>Conclusions</strong></p> <p>In nucleos(t)ide-naive patients with HBeAg-positive CHB, TDF is associated with the highest probability of achieving undetectable HBV DNA at 1 year of all nucleos(t)ides considered.</p>
first_indexed 2024-03-07T08:10:56Z
format Journal article
id oxford-uuid:4fd3c6e2-0441-4cc0-9fe1-08a48fc8a99c
institution University of Oxford
language English
last_indexed 2024-03-07T08:10:56Z
publishDate 2011
publisher Elsevier
record_format dspace
spelling oxford-uuid:4fd3c6e2-0441-4cc0-9fe1-08a48fc8a99c2023-11-23T07:34:48ZMixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis BJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4fd3c6e2-0441-4cc0-9fe1-08a48fc8a99cEnglishSymplectic Elements at OxfordElsevier2011Dakin, HFidler, CHarper, C<p><strong>Background/aims</strong></p> <p>Five nucleoside/nucleotide treatments are now available for chronic hepatitis B (CHB). This meta-analysis aimed to assess the relative efficacy of adefovir, entecavir, lamivudine, telbivudine, tenofovir disoproxil fumarate (TDF), and nucleos(t)ide combinations in the treatment of CHB.</p> <p><strong>Methods</strong></p> <p>A systematic review of MEDLINE and the Cochrane library was conducted to identify all studies evaluating these nucleos(t)ides in adults with CHB. Randomized controlled trials were included in the meta-analysis if they reported the proportion of patients with undetectable hepatitis B virus (HBV) DNA or hepatitis B e antigen (HBeAg) loss/seroconversion at 1 year. Bayesian mixed treatment comparison meta-analyses were conducted in WinBUGS to assess relative efficacy.</p> <p><strong>Results</strong></p> <p>A random-effects meta-analysis of trials on treatment-naive patients with HBeAg-positive CHB demonstrated that 94% of patients will achieve HBV DNA < 300 copies/ml after 1 year with TDF, compared with 73% for entecavir, 50% for adefovir, and 38% for lamivudine. There was a 97.7% probability that TDF enabled a greater proportion of patients to achieve HBV DNA < 300 copies/ml at 1 year than all other treatments considered in the analysis. TDF was significantly superior to all nucleos(t)ides for this outcome at the 0.05 level. There were no statistically significant differences between nucleos(t)ides in HBeAg seroconversion at 1 year, based on a fixed-effects meta-analysis in the same population. More trials on HBeAg-negative and drug-resistant patients are required to facilitate meta-analyses for these subgroups.</p> <p><strong>Conclusions</strong></p> <p>In nucleos(t)ide-naive patients with HBeAg-positive CHB, TDF is associated with the highest probability of achieving undetectable HBV DNA at 1 year of all nucleos(t)ides considered.</p>
spellingShingle Dakin, H
Fidler, C
Harper, C
Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B
title Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B
title_full Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B
title_fullStr Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B
title_full_unstemmed Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B
title_short Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B
title_sort mixed treatment comparison meta analysis evaluating the relative efficacy of nucleos t ides for treatment of nucleos t ide naive patients with chronic hepatitis b
work_keys_str_mv AT dakinh mixedtreatmentcomparisonmetaanalysisevaluatingtherelativeefficacyofnucleostidesfortreatmentofnucleostidenaivepatientswithchronichepatitisb
AT fidlerc mixedtreatmentcomparisonmetaanalysisevaluatingtherelativeefficacyofnucleostidesfortreatmentofnucleostidenaivepatientswithchronichepatitisb
AT harperc mixedtreatmentcomparisonmetaanalysisevaluatingtherelativeefficacyofnucleostidesfortreatmentofnucleostidenaivepatientswithchronichepatitisb